

# Safety and Efficacy of LOW DOse COLchicine in Patients With STATin INTolerance: the LODOCO STINT Pilot Study

NCT06874192

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Virginia Commonwealth University
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- History of statin intolerance (As defined by the NLA 2023 guidelines) Patients who have experienced one or more adverse effects associated with statin therapy, which resolves or improves with dose continuation or reduction
- Stable dose of lipid-lowering regimen (statin or non-statin) for at least one month
- Patients able to provide informed consent.
- Aged 18 to 80 will be enrolled in the study.

### Exclusion (10)

- Known hypersensitivity to colchicine, current use of colchicine or other anti-inflammatory medications.
- Renal impairment (eGFR  $<45$  mL/min/1.73 m<sup>2</sup>)
- Transaminitis (ALT or AST  $>3$  times upper limit of normal)
- Cirrhosis
- Severe Heart Failure
- ... and 5 more (see full listing online)

## Locations (1 total)

---

Virginia Commonwealth University, Richmond, Virginia, United States